Last $292.14 USD
Change Today -0.11 / -0.04%
Volume 1.1K
RHHVF On Other Exchanges
Symbol
Exchange
OTC US
OTC US
OTC US
Xetra
SIX Swiss Ex
Xetra
SIX Swiss Ex
Mexico
Frankfurt
As of 8:10 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

roche holding ag-genusschein (RHHVF) Snapshot

Open
$291.35
Previous Close
$292.25
Day High
$292.21
Day Low
$290.63
52 Week High
02/24/14 - $340.18
52 Week Low
09/5/13 - $247.85
Market Cap
250.4B
Average Volume 10 Days
2.7K
EPS TTM
--
Shares Outstanding
702.6M
EX-Date
03/6/14
P/E TM
--
Dividend
$8.13
Dividend Yield
3.03%
Current Stock Chart for ROCHE HOLDING AG-GENUSSCHEIN (RHHVF)

roche holding ag-genusschein (RHHVF) Related Bloomberg News

View More Bloomberg News

roche holding ag-genusschein (RHHVF) Details

Roche Holding AG operates in the pharmaceuticals and diagnostics businesses in Switzerland, European Union, and internationally. It discovers, develops, and provides diagnostic and therapeutic products and services that enable patients and healthcare professionals in the detection, prevention, diagnosis, treatment, and treatment monitoring of diseases. The company provides pharmaceutical products for various therapeutic areas comprising oncology, virology, inflammation, metabolic disorders, and central nervous system. In addition, it offers a portfolio of diagnostics products, such as blood glucose meters for diabetes patients; point-of-care testing devices for use in doctors’ offices; high-throughput analyzers for hospitals and commercial diagnostic laboratories; and start-of-the-art instruments and reagents for life science research. The company has a collaboration agreement with Astrazeneca Plc to develop a plasma-based companion diagnostic test to support AZD9291, a drug candidate for treating non-small-cell lung cancer; and a collaboration agreement with AmorChem L.P. to discover novel small molecule disease-modifying therapy for the treatment of myotonic muscular dystrophy 1 or Steinert's disease. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland.

85,080 Employees
Last Reported Date: 01/30/14
Founded in 1896

roche holding ag-genusschein (RHHVF) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: SFr.5.1M
Compensation as of Fiscal Year 2013.

roche holding ag-genusschein (RHHVF) Key Developments

Chugai Denies Rumor Of Talks With Roche

Chugai Pharmaceutical Co. Ltd. (TSE:4519) denies a rumor that Roche Holding AG (SWX:ROG) was in talks to buy 40% stake of Chugai Pharmaceutical that it does not already own for $10 billion.

Roche Holding Reportedly In Talks To Chugai Pharmaceutical

Roche Holding AG (SWX:ROG) is in talks to buy the almost additional 40% stake in Chugai Pharmaceutical Co. Ltd. (TSE:4519) for about $10 billion, Bloomberg reported citing people familiar with the matter. A deal could be announced as early as next week, although no final decision has been made. A Chugai Pharmaceutical Co. Ltd.'s statement said the company is “in no way in the process of reviewing any plan to become a wholly owned subsidiary of Roche.” Representatives for Roche Holding AG declined to comment.

Investors Reportedly Eyes Stake In InterMune

Sanofi SA-(Sanofi AG) and Roche Holding AG (SWX:ROG) are the bidders to acquire InterMune, Inc. (NasdaqGS:ITMN), people with knowledge of the matter said. Also bidding for InterMune are GlaxoSmithKline plc (LSE:GSK) and Actelion Ltd. (SWX:ATLN), said the people, asking not to be identified because the process is private. Sanofi has so far shown the most interest in a deal, one person said. Goldman Sachs Group Inc. and Centerview Partners LLC are helping InterMune sort through bids for the business, the people said. Representatives for InterMune, Sanofi (SAN), Actelion, Roche, GlaxoSmithKline, and Goldman Sachs declined to comment. Representatives for Centerview couldn’t be reached. Shares of InterMune went up by 14% to $52.06.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RHHVF:US $292.14 USD -0.11

RHHVF Competitors

Market data is delayed at least 15 minutes.

Company Last Change
General Electric Co $25.98 USD -0.03
Gilead Sciences Inc $107.56 USD +0.05
Johnson & Johnson $103.73 USD +0.78
Merck & Co Inc $60.11 USD +0.11
Novartis AG SFr.82.35 CHF +0.35
View Industry Companies
 

Industry Analysis

RHHVF

Industry Average

Valuation RHHVF Industry Range
Price/Earnings 20.7x
Price/Sales 4.5x
Price/Book 12.6x
Price/Cash Flow 16.9x
TEV/Sales 3.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ROCHE HOLDING AG-GENUSSCHEIN, please visit www.roche.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.